Evidence map›Paper›PMID 40275954›Full record

ArticleMaterials today. Bio2025

Bioactive deproteinized bovine bone mineral based on self-assembled albumin nanoparticles promoted bone regeneration via activation of Wnt/β-catenin pathway.

Ya-Wen Zhu, Yu-Wen Wei, Jing-Yi Ma, Wei Chen, Zhe Shen, Jing Qiu

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ya-Wen ZhuDepartment of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.
Yu-Wen WeiDepartment of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.
Jing-Yi MaDepartment of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.
Wei ChenDepartment of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.
Zhe ShenDepartment of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.
Jing QiuDepartment of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the major problems faced with pre-implant bone reconstruction therapy is that large bone defects do not heal over time. Artificial bone graft materials, such as deproteinized bovine bone mineral, are commonly used in clinics. However, the lack of osteoinductive capacity and risk of post-implantation infections remain key limitations. Bioactive materials with strong bone formation and a high degree of biocompatibility are still needed. In this study, we synthesised bovine serum albumin nanoparticles (BNP) loaded with Tideglusib (TD), TD and BNP were bound together by self-assembly, and mixed with deproteinized bovine bone mineral (DBBM) to form a bone substitute material (TD-BNP@DBBM) that had low cytotoxicity, promoted cell proliferation and migration, induced cell differentiation, and regulated osteogenesis. In vitro, experiments suggested that TD-BNP@DBBM could promote osteoblast differentiation of MC3T3-E1 cells. In vivo, experiments demonstrated that TD-BNP@DBBM significantly accelerated bone reconstruction and enhanced bone healing in a rat cranial defect model. Furthermore, this result suggested a link between the Wnt/β-catenin pathway and the osteogenic effect, providing a basis for subsequent investigations into the mechanism of bone regeneration induced by osteogenic biomaterials. TD-BNP@DBBM might be a promising new approach for treating bone defects.

Indexed as

Bone regenerationOsteogenesisTD-BNP@DBBMWnt/β-catenin

Identifiers

PMID40275954
PMCPMC12018063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.